Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients

Jinsun Woo1, Geumhee Gwak2, Inseok Park2, Byung Noe Bae2, Se Kyung Lee1, Byung Joo Chae1, Jonghan Yu1, Jeong Eon Lee1, Seok Won Kim2, Seok Jin Nam1 & Jai Min Ryu1*

Decision to undergo risk-reducing mastectomy (RRM) needs to consider several factors, including patient's preference, surgeon's preference, family history, and genetic predisposition. The aim of this study was to examine whether preoperative diagnosis of BRCA1/2 mutation status could influence surgical decision-making in newly diagnosed breast cancer patients. We retrospectively reviewed ipsilateral breast cancer patients with BRCA1/2 mutation who underwent primary surgery between January 2008 and November 2019 at a single institution in Korea. Of 344 eligible patients, 140 (40.7%) patients were aware of their mutation status prior to surgery, while 204 (59.3%) did not. Contralateral RRM rate was significantly higher in the group with BRCA1/2 mutation status identified prior to surgery compared to the group with mutation status identified after surgery [45.0% (63/140) vs. 2.0% (4/204)] (p < 0.001). Reduced turnaround time of BRCA1/2 testing (p < 0.001) and the use of neoadjuvant chemotherapy (p < 0.001) were associated with BRCA1/2 mutation status identified prior to surgery. Although not statistically significant, higher incidence of developing contralateral breast cancer for BRCA1/2 mutation carriers who underwent ipsilateral surgery-only compared to those who underwent contralateral RRM was observed [12.1% (95% CI: 7.7–17.7%)] (p = 0.1618). Preoperative diagnosis of BRCA1/2 mutation could impact surgical decision-making for breast cancer patients to undergo risk-reducing surgery at the time of initial surgery.

A celebrity's announcement of having a BRCA1 mutation and undergoing bilateral risk-reducing mastectomy (RRM) has influenced breast cancer patients and women with high-risk breast cancer. The so-called "Angelina's effect" has impacted public's health awareness of hereditary breast cancer and increased rates of genetic counseling and tests for BRCA1/2 mutations1–3. This has also led to an increase in the rate of RRM among women with inherited BRCA1/2 mutation.

BRCA1/2 mutation carriers who have developed breast cancer have a significant higher risk for ipsilateral breast recurrence with a median follow-up ≥7 years compared to non-carriers4. These patients also have an elevated risk of developing contralateral breast cancer, with a cumulative incidence up to 83% for BRCA1 and 62% for BRCA2 carriers5–7. Although the efficacy of contralateral RRM for women with BRCA1/2 mutation has been controversial, many studies have suggested a marked decrease of cancer in the opposite breast8–10. Therefore, newly diagnosed breast cancer patients with BRCA1/2 mutation can consider bilateral mastectomy as a treatment option regarding risk-reducing measures. Decision to undergo RRM needs to consider several factors such as patient's preference, surgeon's preference, subtype of breast cancer, clinical stage, family history, and genetic predisposition11–13.

In this current study, we investigated whether the timing of identification of BRCA1/2 mutation might affect surgical decision making. Some studies have shown that genetic diagnosis prior to surgery is associated with RRM12,14,15. With growth in the number of genetic testing and the development of sequencing technologies, we further investigated factors that enabled patients to obtain knowledge of BRCA1/2 mutation status prior to

1Division of Breast Surgery, Department of Surgery, Samsung Medical Center Cancer Hospital, Sungkyunkwan University School of Medicine, 5th Floor Breast-Endocrine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea. 2Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea. *email: snowman120@hanmail.net
initial surgery. In addition, we analyzed oncologic outcomes of BRCA1/2 mutation carriers with breast cancer according to types of surgery.

**Methods**

We conducted a retrospective review of breast cancer patients tested for BRCA1/2 mutations between January 2008 and November 2019 who underwent curative surgery at Samsung Medical Center. Patients were eligible for this study if they underwent upfront surgery or surgery following neoadjuvant chemotherapy. Genetic testing was conducted at any time in relation to their diagnosis of breast cancer or surgery. They were identified to carry a deleterious BRCA1/2 mutation. We excluded patients who had a history of previous breast cancer, bilateral breast cancer, stage IV disease, those who had not undergone a curative breast surgery, and male patients.

Patients with breast cancer were routinely transferred to a dedicated genetic counselor for pre-test counseling and BRCA1/2 testing on the first visit to our outpatient clinic if the following criteria were met and patients agreed. Criteria for BRCA1/2 testing were as follows: family history of breast and/or ovarian cancer in first- or second-degree relative, diagnosis of breast cancer at 40 years old or younger, bilateral breast cancer, and multiple primary cancers including breast cancer. Post-test counseling was provided to individuals to inform results of testing and discuss treatment options.

We collected information from registered medical records, including age at breast cancer diagnosis, types of breast surgery, administration of neoadjuvant chemotherapy, pathologic staging, tumor characteristics, types of adjuvant therapy, and patient outcome. Patients were categorized as 'BRCA1/2 mutation status known prior to surgery' if their date of BRCA1/2 testing result was earlier than the date of surgery and 'BRCA1/2 mutation status known after surgery' if their results were yielded on the day of surgery or after surgery. We additionally calculated turnaround time (TAT) of each testing defined by the time interval between the submission of the patient's peripheral blood and delivery of the verified result.

BRCA1/2 testing was performed using genomic DNA isolated from peripheral blood. The sequencing method was initially Sanger sequencing. It was then transitioned to next generation sequencing after September 2016. We classified 'pathogenic' or 'likely pathogenic' results as positive mutation for BRCA1/2, while results of 'benign', 'likely benign', or 'uncertain significance' were classified as negative mutations.16

Comparison of patients with BRCA1/2 mutation identified prior to surgery and those after surgery was performed using the Chi-Square test or Fischer's exact test for categorical variables and Wilcoxon rank sum test for continuous variables. Multivariable analysis using logistic regression with backward variable selection was conducted to identify factors associated with BRCA1/2 mutation status known prior to surgery. Kaplan–Meier curves were used to analyze recurrence-free survival (RFS) and overall survival (OS). Log-rank tests were used to compare survival outcomes between patients who underwent ipsilateral surgery only and patients who underwent contralateral RM. Cumulative incidence function plot was used to analyze the 5-year cumulative incidence of contralateral breast cancer. Gray's test was used to compare outcomes between the two groups. All statistical analyses were executed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R 3.6.1 (Vienna, Austria; http://www.R-project.org/). A P-value of < 0.05 was considered statistically significant.

All study procedures were conducted in accordance with the Declaration of Helsinki and were approved by the Institutional Review Board (IRB) of Samsung Medical Center, South Korea (IRB File No. 2020-12-145). The requirement for informed consent was waived by the IRB of Samsung Medical Center because of the retrospective nature of this study.

**Results**

**Patient characteristics.** Among 3950 breast cancer patients who were tested for BRCA1/2 mutation between January 2008 and November 2019 in Samsung Medical Center, 486 patients were BRCA1/2 mutation carriers. A total of 344 patients were eligible for the final analysis. Of the final cohort, 140 (40.7%) patients had their BRCA1/2 mutation status identified prior to surgery (Group 1), while 204 (59.3%) were aware of their mutation status after surgery (Group 2) (Table 1). Women in Group 1 were younger (37.5 years vs 42.0 years, p < 0.001) with shorter TAT of BRCA1/2 mutation testing compared to Group 2 (21 days vs 29 days, p < 0.001). Almost two thirds (60.7%) of subjects in Group 1 received neoadjuvant chemotherapy as primary treatment, whereas 89.2% of patients in the Group 2 underwent surgery as primary treatment (p < 0.001). Higher clinical T stage and N stage were observed in Group 1 than in Group 2. Additionally, subjects in Group 1 were less likely to be treated with adjuvant chemotherapy (42.9% vs 73.4%) and radiotherapy (60.7% vs 80.8%). Proportions of BRCA1/2 mutations, histology, and biologic subtype were not significantly different between the two groups. Out of 14 patients with HER2 positive receptors, 12 received anti-HER2 therapy, and the remaining two with ductal carcinoma in situ did not receive such therapy.

**Types of surgery according to preoperative knowledge of BRCA1/2 mutations.** As shown in Fig. 1, contralateral RRM was performed for 45.0% (63/140) of patients with BRCA1/2 mutation identified prior to surgery. The rate was significantly (p < 0.001) lower for patients with BRCA1/2 mutation identified after surgery, of which only 2.0% (4/204) chose contralateral RRM as initial surgery whereas 72.5% (148/204) elected ipsilateral partial mastectomy and 25.5% (52/204) elected ipsilateral total mastectomy. Out of the whole cohort, 13 patients eventually underwent bilateral mastectomy after their initial surgery, including 8 patients whose BRCA1/2 mutation were identified after the initial surgery, 1 patient who was a known BRCA1/2 mutation carrier prior to initial surgery, and 4 who developed contralateral breast cancer.

**Factors associated with BRCA1/2 mutation status known prior to surgery.** Multivariable analysis was conducted using factors that were significant in univariable analysis, including patient age, TAT of
| Characteristic                                | BRCA status known prior to surgery (Group 1) | BRCA status known after surgery (Group 2) | Total | p value |
|----------------------------------------------|-----------------------------------------------|-------------------------------------------|-------|---------|
| Age (years)                                  |                                               |                                           |       | 0.027   |
| Median, ranges                               | 37.5 (23.0–67.0)                              | 42.0 (25.0–75.0)                          | 39.0 (23.0–75.0) |         |
| ≤ 40                                         | 89 (63.6%)                                    | 95 (46.6%)                                | 184 (53.5%) | 0.002   |
| > 40                                         | 51 (36.4%)                                    | 109 (53.4%)                               | 160 (46.5%) |         |
| Turnaround time of BRCA1/2 testing (days)    |                                               |                                           |       | <0.001  |
| Median, ranges                               | 21 (8–85)                                     | 29 (8–97)                                 | 27.0 (8–97) |         |
| Family history of breast cancer              |                                               |                                           |       |         |
| Yes                                          | 89 (64.0%)                                    | 125 (61.3%)                               | 214 (62.4%) |         |
| No                                           | 50 (36.0%)                                    | 79 (38.7%)                                | 129 (37.6%) |         |
| Missing data                                 | 1                                             |                                           |       |         |
| BRCA1/2 results                              |                                               |                                           |       | 0.096   |
| BRCA1 mutation                               | 76 (54.3%)                                    | 92 (45.1%)                                | 168 (48.8%) |         |
| BRCA2 mutation                               | 63 (45.0%)                                    | 110 (53.9%)                               | 173 (50.3%) |         |
| BRCA1 and BRCA2 mutations                    | 1 (0.7%)                                      | 2 (1.0%)                                  | 3 (0.9%)  |         |
| Histology                                    |                                               |                                           |       | 0.783   |
| Invasive ductal carcinoma                    | 127 (90.7%)                                   | 183 (89.7%)                               | 310 (90.1%) |         |
| Invasive lobular carcinoma                   | 3 (2.1%)                                      | 3 (1.5%)                                  | 6 (1.7%)  |         |
| Ductal carcinoma in situ                     | 4 (2.9%)                                      | 11 (5.4%)                                 | 15 (4.4%)  |         |
| Others                                       | 6 (4.3%)                                      | 7 (3.4%)                                  | 13 (3.8%)  |         |
| Ki-67                                        |                                               |                                           |       | 0.319   |
| > 20%                                        | 111 (79.9%)                                   | 152 (75.2%)                               | 263 (77.1%) |         |
| ≤ 20%                                        | 28 (20.1%)                                    | 50 (24.8%)                                | 78 (22.9%) |         |
| Missing data                                 | 1                                             | 2                                         | 3     |         |
| Biologic subtype                             |                                               |                                           |       | 0.847   |
| HR+/HER2−                                    | 75 (54.0%)                                    | 105 (52.5%)                               | 180 (53.1%) |         |
| HR+/HER2 +                                   | 2 (1.4%)                                      | 6 (3.0%)                                  | 8 (2.4%)   |         |
| HR−/HER2−                                    | 4 (2.9%)                                      | 2 (1.0%)                                  | 6 (1.8%)   |         |
| HR−/HER2−                                    | 58 (41.7%)                                    | 87 (43.5%)                                | 145 (42.8%) |         |
| Missing data                                 | 1                                             | 4                                         | 5     |         |
| Clinical T stage                             |                                               |                                           |       | <0.001  |
| T0                                           | 4 (2.9%)                                      | 12 (5.9%)                                 | 16 (4.7%)  |         |
| T1                                           | 39 (28.1%)                                    | 100 (49.0%)                               | 139 (40.5%) |         |
| T2                                           | 66 (47.5%)                                    | 78 (38.2%)                                | 144 (42.0%) |         |
| T3                                           | 28 (20.1%)                                    | 14 (6.9%)                                 | 42 (12.2%)  |         |
| T4                                           | 2 (1.4%)                                      | 0 (0.0%)                                  | 2 (0.6%)   |         |
| Missing data                                 | 1                                             | 0                                         | 1     |         |
| Clinical N stage                             |                                               |                                           |       | <0.001  |
| N0                                           | 67 (48.2%)                                    | 136 (66.7%)                               | 203 (59.2%) |         |
| N1                                           | 26 (18.7%)                                    | 41 (20.1%)                                | 67 (19.5%)  |         |
| N2                                           | 27 (19.4%)                                    | 20 (9.8%)                                 | 47 (13.7%)  |         |
| N3                                           | 19 (13.7%)                                    | 7 (3.4%)                                  | 26 (7.6%)   |         |
| No axillary surgery                          | 1                                             | 0                                         | 1     |         |
| Primary treatment                            |                                               |                                           |       | <0.001  |
| Neoadjuvant chemotherapy followed by surgery | 85 (60.7%)                                    | 22 (10.8%)                                | 107 (31.1%) |         |
| Upfront surgery                              | 55 (39.3%)                                    | 182 (89.2%)                               | 237 (68.9%) |         |
| Pathologic T stage                           |                                               |                                           |       | 0.009   |
| T0                                           | 33 (23.6%)                                    | 13 (6.4%)                                 | 46 (13.4%)  |         |
| T1                                           | 65 (46.4%)                                    | 111 (54.4%)                               | 176 (51.2%) |         |
| T2                                           | 31 (22.1%)                                    | 74 (36.3%)                                | 105 (30.5%) |         |
| T3                                           | 11 (7.9%)                                     | 6 (2.9%)                                  | 17 (4.9%)   |         |
| Pathologic N stage                           |                                               |                                           |       | 0.760   |
| N0                                           | 99 (70.7%)                                    | 132 (67.3%)                               | 231 (68.8%) |         |
| N1                                           | 29 (20.7%)                                    | 48 (24.5%)                                | 77 (22.9%)  |         |
| N2                                           | 9 (6.4%)                                      | 13 (6.6%)                                 | 22 (6.5%)   |         |
| N3                                           | 3 (2.1%)                                      | 3 (1.5%)                                  | 6 (1.8%)   |         |
| No axillary surgery                          | 0                                             | 8                                         | 8     |         |

Continued
BRCA1/2 testing, higher clinical T, N stage, and neoadjuvant chemotherapy (Table 2). Patients were significantly more likely to be informed of BRCA mutation status if they received neoadjuvant chemotherapy (OR: 22.43; 95% CI: 11.26–44.64) or their TAT of testing was significantly associated with BRCA1/2 mutation status known prior to surgery.

Oncologic outcomes of BRCA1/2 mutation carriers with breast cancer according to types of initial surgery.

Of 344 patients in the cohort, 67 (19.5%) patients underwent contralateral RRM and 277 (80.5%) patients underwent ipsilateral surgery as initial surgery. The median follow-up was 41 months for the total patients, 46 months for the ipsilateral surgery only group, and 15 months for the contralateral RRM group. There was no significant difference in overall survival (log-rank \( p = 0.938 \)) or disease-free survival (log-rank \( p = 0.864 \)) between the two surgery groups. No patient in the contralateral RRM group experienced contralateral breast cancer during the follow-up. However, 10.8% (30/277) of the ipsilateral surgery-only group developed contralateral breast cancer. The estimated 5-year cumulative incidence of contralateral breast cancer was 12.1% (95% CI 7.7–17.7%) for the ipsilateral surgery-only group. This incidence was not available for the contralateral RRM group because contralateral breast cancer did not occur (Fig. 2).

Median TATs for BRCA1/2 testing.

Annual number of cases tested positive for BRCA1/2 mutation who underwent curative breast cancer surgery and median TATs for BRCA1/2 testing in Samsung Medical Center is shown in Fig. 3. A definite increase in the BRCA1/2 mutation carriers was observed in 2014. Since then, pro-

| Characteristic                  | BRCA status known prior to surgery (Group 1) | BRCA status known after surgery (Group 2) | Total     | \( p \) value |
|--------------------------------|---------------------------------------------|------------------------------------------|-----------|----------------|
| Adjuvant chemotherapy          |                                              |                                          |           | < 0.001       |
| Yes                            | 60 (42.9%)                                  | 149 (73.4%)                              | 209 (60.9%)|                |
| No                             | 80 (57.1%)                                  | 54 (26.6%)                               | 134 (39.1%)|                |
| Missing data                   | 0                                           | 1                                        | 1         |                |
| Adjuvant radiotherapy          |                                              |                                          |           | < 0.001       |
| Yes                            | 85 (60.7%)                                  | 164 (80.8%)                              | 249 (72.6%)|                |
| No                             | 55 (39.3%)                                  | 39 (19.2%)                               | 94 (27.4%) |                |
| Missing data                   | 0                                           | 1                                        | 1         |                |
| Adjuvant hormone therapy       |                                              |                                          |           | 0.975          |
| Yes                            | 78 (55.7%)                                  | 114 (55.9%)                              | 192 (55.8%)|                |
| No                             | 62 (44.3%)                                  | 90 (44.1%)                               | 152 (44.2%)|                |
| Total                          | 140 (40.7%)                                 | 204 (59.3%)                              | 344 (100.0%)|                |

Table 1. Clinicopathological and treatment characteristics of patients. HR hormone receptor, HER2 human epidermal growth factor receptor 2. ‘Pathologic T stage and pathologic N stage include post neoadjuvant therapy pathological category.

Figure 1. Types of surgery according to the timing of identification of BRCA1/2 mutation status. PM partial mastectomy, TM total mastectomy, RRM risk reducing mastectomy.
portions of patients with known $BRCA1/2$ status prior to surgery to $BRCA1/2$ mutation carriers have steadily increased. The bold line indicates the median value of TATs. The median TAT dropped from 49 days in 2016 to 15 days in 2019.

**Discussion**

In the present study, concomitant contralateral RRM was significantly more prevalent in breast cancer patients whose $BRCA1/2$ mutations were identified prior to surgery. We found that most patients underwent either ipsilateral partial mastectomy or ipsilateral total mastectomy when their mutation status was unknown at initial surgery. This is line with earlier studies reporting that preoperative genetic testing impacts surgical decision making in favor of RRM [12,14,15,17,18]. We additionally demonstrated several factors that enabled patients to gain knowledge about their $BRCA1/2$ mutation status prior to initial surgery. Although not statistically significant,
we observed a higher risk of developing contralateral breast cancer for BRCA1/2 mutation carriers who under- went ipsilateral surgery-only compared to those who underwent contralateral RRM. Preoperative testing and diagnosis of BRCA1/2 mutation provided opportunities for patients to engage in risk reducing measures at the time of primary surgery.

Short TATs of sequencing for BRCA1/2 mutation allowed patients to receive their results before the initial surgery. A study has assessed TATs of BRCA1/2 testing among ovarian cancer patients and revealed that amount of time it takes from initial genetic counseling to receipt of testing results is mainly driven by sample processing time, with median TATs varied among countries (2.7 weeks, 14.6 weeks, and 5.9 weeks in the US, Italy, and Spain, respectively)19. In our study, the median TAT in the group that mutation status was known prior to surgery was 21 days, whereas the median TAT in the group that mutation status was identified after surgery was 30 days. Traditionally, genetic testing to identify BRCA1/2 mutation has been conducted by Sanger sequencing. Sanger sequencing analysis generally requires 4 to 6 weeks of TAT in South Korea, making it difficult for patients to obtain genetic information preoperatively20. The development of next-generation sequencing (NGS) and its application for detecting genetic mutations have significantly shortened the analysis time and lowered the expenditure. Our institution adopted NGS for identifying BRCA1/2 mutations in late 2016. We have observed reduced TATs since then, proven by decreasing line graph shown in Fig. 3. Our previous retrospective study included 164 BRCA1/2 mutation carriers who underwent curative breast cancer surgery between 2004 and 2015 and identified only 15 patients with known BRCA mutation prior to surgery15. The current study expanded the inclusion period until late 2019. The number of patients with known BRCA1/2 mutation status prior to surgery was increased up to 140. Recent increase of patients with BRCA1/2 mutation status identified prior to surgery could be explained by the application of NGS on BRCA1/2 mutation testing which reduced TATs and increased the use of neoadjuvant chemotherapy.

Our study demonstrates that undergoing neoadjuvant chemotherapy has great odds of gaining knowledge of BRCA1/2 mutation status prior to surgery. It allows the time it takes for genetic testing to yield results while patients are treated. However, out of 107 patients who underwent neoadjuvant chemotherapy, 22 patients did not receive results preoperatively. This was mainly due to late identification of patients with high risk of hereditary breast cancer or delayed prescription of BRCA1/2 mutation testing.

Trained personnel, training programs, and formal accreditation processes are essential for accessibility to genetic counselling and testing. South Korea has implemented a national program for genetic counselling and genetic testing through national healthcare system, which has eventually increased proportions of genetic testing uptake to breast cancer incidence of 7.7%, the highest in Asia21. A prior study has indicated that early detection and genetic referral of patients who meet guidelines for BRCA1/2 testing are important for receiving testing results prior to surgery14. According to the American BRCA Outcomes and Utilization of Testing (ABOUT) Study22, lack of physician recommendation is the most commonly reported reason for not receiving genetic counseling. In our clinic, genetic counseling and testing are offered to patients with high risk of hereditary breast cancer on the first day of visit following breast cancer diagnosis. A concept of rapid genetic counseling and testing (RGCT) in newly diagnosed breast cancer patients is being emphasized. In order to maximize the likelihood that test results can be used for surgical decision, surgeons need to provide genetic testing at the point of care. They could even delay primary surgery slightly for a small subset of high-risk patients23–25.

Figure 3. Bar and line graph showing number of cases tested positive for BRCA1/2 who underwent curative breast cancer surgery and median turnaround time for BRCA1/2 testing in Samsung Medical Center. TAT turnaround time.

![Graph showing number of cases tested positive for BRCA1/2 who underwent curative breast cancer surgery and median turnaround time for BRCA1/2 testing in Samsung Medical Center. TAT turnaround time.](https://example.com/graph.png)
In this study, contralateral RRM demonstrated no survival benefit for BRCA1/2 mutation carriers with breast cancer. This is in line with a meta-analysis by Valanchis, stating that there is no significant difference in breast-cancer-specific survival between BRCA1/2 carriers who undergo contralateral RRM and breast conserving therapy. However, mortality benefit from preventing contralateral second primary cancer is likely to be apparent after an extended period of follow-up. Metcalf et al. have noted a 48% reduction of death from breast cancer in BRCA1/2 mutation carriers who undergo contralateral RRM compared to those who undergo ipsilateral mastectomy after a 20-year follow-up.

The greater risk of developing contralateral breast cancer in BRCA1/2 mutation carriers compared to women with sporadic cancer supports the necessity of RRM for the unaffected side of breast for BRCA1/2 mutation carriers. The cumulative incidence for mutation carriers vs. sporadic cases is 20% vs. 2% at 5 years and 42% vs 9% at 12 years. A previous case–control study conducted in our center has shown 4.0% of metachronous contralateral breast cancer recurrence in BRCA1/2-negative patients with risk factors for hereditary breast and/or ovarian cancer. However, the current study showed 8.4% of metachronous contralateral breast cancer recurrence in patients with BRCA1/2 mutations.

Several studies have concluded that contralateral RRM could reduce the risk among BRCA1/2 mutation carriers with a history of breast cancer. Van Sprundel et al. have reported a reduction of contralateral breast cancer risk by 91%, independent of the effect of bilateral prophylactic oophorectomy. Patients in our cohort who underwent contralateral RRM did not develop any contralateral breast cancer. The 5-year cumulative incidence of contralateral breast cancer patients who underwent ipsilateral surgery only was 12.1%. However, the difference in the risk of contralateral breast cancer between those two groups was insignificant. This might be due to a follow-up time as short as 15 months for the contralateral RRM group. The Korean National Health Insurance coverage for contralateral breast surgery in breast cancer patients with BRCA1/2 mutation carrier was initiated in March 2017 and the first patient in our cohort to receive contralateral RRM was in April 2014. These conditions might have resulted in a relatively short median follow-up time for the contralateral RRM group.

Decision to undergo RRM is a complex process, which involves weighing the benefits and harms. Of 140 patients with BRCA1/2 mutation status identified prior to surgery, 77 (55%) did not choose RRM as their initial surgery. Previous studies stated that reasons for not opting RRM include its lack of survival benefit, increased operative morbidity, potential to delay adjuvant therapy if complications occur, and possible poor cosmetic outcome. Benefits for undergoing RRM include reducing the risk of contralateral breast cancer and possibilities of avoiding additional treatment. Patients who were unaware of their BRCA1/2 status and underwent partial mastectomy received radiotherapy. If they eventually undergo mastectomy and reconstruction afterwards, previous radiation could elicit complications. Of 30 patients who developed contralateral breast cancer in our cohort, 11 (36.7%) were triple-negative breast cancer. All 30 patients underwent subsequent curative surgery, 13 (43.3%) received chemotherapy, and 15 (50.0%) received radiotherapy. These additional treatments could have been spared if BRCA1/2 carriers with unilateral breast cancer underwent RRM at the time of initial surgery. Furthermore, although intensive surveillance could be opted for BRCA2 carriers due to low mortality, women electing for RRM want to avoid the lifelong distress related to intensive surveillance.

This study has several limitations. First, this was a retrospective analysis of patients treated at a single institution, which could limit the generalizability of our findings. Second, the criterion used to categorize patients was ‘date of BRCA1/2 testing result’, which could lead to overestimation of patients with BRCA1/2 mutation status known prior to surgery. Thirteen patients had no actual record about delivery of mutation status prior to surgery. However, all patients in the cohort received pre-test counseling. In addition, we routinely informed BRCA1/2 testing result even on the day before surgery. Third, factors that could affect surgical decision to undergo RRM were not analyzed. We demonstrated that reduced TATs and treating with neoadjuvant chemotherapy enabled patients to be aware of BRCA1/2 mutation status preoperatively. These factors could potentially affect surgical decision-making. However, their direct associations with increased RRM were not proved. Lastly, our oncologic outcomes have limitation for interpretation due to the short follow-up time for the ipsilateral surgery-only group and lack of adjustment for factors that affect outcomes such as age and use of adjuvant therapy. Further investigation on oncologic outcomes with an extended period of follow-up and adjustment for clinical variables is required. These limitations were countered by the significance of present study. We demonstrated that long TAT of gene testing as well as lack of systemized genetic counseling, delay in referral of patients to genetic counselor impeded patients’ preoperative awareness of BRCA1/2 mutation status. As far as we know, it is the first to present such results in Asia.

Conclusions
In conclusion, our findings demonstrate that preoperative identification of BRCA1/2 mutation could affect surgical decision-making for breast cancer patients in favor of contralateral RRM. With the application of NGS for BRCA1/2 testing and the use of neoadjuvant chemotherapy, more patients are able to acquire their mutation status prior to initial surgery. Although undergoing contralateral RRM may not guarantee improved survival, it could reduce contralateral breast cancer risk, contribute to the reduction of additional future surgeries, unnecessary adjuvant radiation, and improve patient satisfaction. It is important that clinicians provide genetic counseling and testing at the time of diagnosis in order to inform patients of their BRCA1/2 mutation status prior to surgery and provide them with optimal treatment options.

Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References

1. Liede, A. et al. Risk-reducing mastectomy rates in the US: A closer examination of the Angelina Jolie effect. Breast Cancer Res. Treat. 171, 435–442 (2018).
2. Lee, J. et al. Influence of the Angelina Jolie announcement and insurance reimbursement on practice patterns for hereditary breast cancer. J. Breast Cancer 20, 203–207 (2017).
3. Evans, D. G. et al. The Angelina Jolie effect: How high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 16, 442 (2014).
4. Lokich, E. et al. Surgical management of breast cancer in BRCA mutation carriers: A systematic review and meta-analysis. Breast Cancer Res. Treat. 144, 443–453 (2014).
5. van der Kolk, D. M. et al. Penetration of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: High cancer incidence at older age. Breast Cancer Res. Treat. 124, 643–651 (2010).
6. Mavaddat, N. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 105, 812–822 (2013).
7. Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
8. van Sprundel, T. C. et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br. J. Cancer 93, 287–292 (2005).
9. Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93, 1633–1637 (2001).
10. Kaas, R. et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: Very low risk for subsequent breast cancer. Ann. Surg. 251, 488–492 (2010).
11. Yildiz, M. et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev. Res. (Phila) 3, 1026–1034 (2010).
12. Yadav, S., Reeves, A., Campian, S., Sufka, A. & Zakalik, D. Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: A retrospective cohort analysis. Hered. Cancer Clin. Pract. 15, 11 (2017).
13. Arrington, A. K., Jarosek, S. L., Vornig, B. A., Habermann, E. B. & Tuttle, T. M. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann. Surg. Oncol. 16, 2697–2704 (2009).
14. Chuba, A. et al. Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer. Ann. Surg. Oncol. 23, 3232–3238 (2016).
15. Park, S. et al. Genetic diagnosis after surgery has an impact on surgical decision in BRCA1 mutation carriers with breast cancer. World J. Surg. 42, 1384–1390 (2018).
16. National Human Genome Research Institute. Breast Cancer Information Core. https://research.nhgri.nih.gov/bic/. Accessed 1 Oct 2020.
17. Lokiech, E. et al. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol 134, 326–330 (2014).
18. Wevers, M. R. et al. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: Retrospective data from the Dutch HEBON study. Fam. Cancer 14, 355–363 (2015).
19. Colombo, N. et al. Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. J. Clin. Oncol. 36, 1300–1307 (2018).
20. Park, H. S. et al. Next-generation sequencing of BRCA1/2 in breast cancer patients: Potential effects on clinical decision-making using rapid, high-accuracy genetic results. Ann. Surg. Oncol. 92, 331–339 (2017).
21. Nakamura, S. et al. Current status of the management of hereditary breast and ovarian cancer in Asia: First report by the Asian BRCA consortium. Public Health Genomics 19, 53–60 (2016).
22. Armstrong, J. et al. Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: The ABOUT study. JAMA Oncol. 1, 1251–1260 (2015).
23. Wevers, M. R. et al. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: Findings from a randomised controlled trial. Br. J. Cancer 110, 1081–1087 (2014).
24. Schwartz, M. D. et al. Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients. Breast Cancer Res. Treat. 170, 517–524 (2018).
25. Cortesi, L. et al. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women. Ann. Oncol. 25, 57–63 (2014).
26. Metcalfe, K. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis, BMJ 348, g226 (2014).
27. Narod, S. A. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res. Treat. 128, 581–583 (2011).
28. Kirova, Y. M. et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur. J. Cancer 41, 2304–2311 (2005).
29. Pierce, L. J. et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J. Clin. Oncol. 18, 3360–3369 (2000).
30. Haffty, B. G. et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359, 1471–1477 (2002).
31. Ryu, J. M. et al. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. Jpn. J. Clin. Oncol. 50, 104–113 (2020).
32. Li, X. et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Clin. Cancer Res. 22, 3971–3981 (2016).
33. Heemskerk-Gerritsen, B. A. et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Int. J. Cancer. 136, 668–677 (2015).
34. Carbone, N. E., Lovestumo, L., Wallace, J. & Ko, H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 4, CD002748 (2018).
35. Montagna, G. & Morrow, M. Contralateral prophylactic mastectomy in breast cancer: What to discuss with patients. Expert Rev. Anticancer Ther. 20, 159–166 (2020).
36. Neven, P. et al. Risk-reducing mastectomy in BRCA carriers: Survival is not the issue. Breast Cancer Res. Treat. 179, 251–252 (2020).

Author contributions

J.M.R. conceptualized, designed the study, and critically revised the manuscript. J.W. designed the study, acquired, analyzed the data, performed statistical analyses, and drafted the manuscript. G.G. analyzed, interpreted data
and revised the manuscript. S.K.L., B.J.C., J.Y., and J.E.L. supervised data collection, analyzed and interpreted data. B.N.B., I.P., S.W.K., and S.J.N. critically reviewed the manuscript. All authors have read and approved the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to J.M.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021